Investor Announcements - 2016

Pages:

TR-1 notification of major interest in shares

21^st Mar 2016

Second Price Monitoring Extension

17^th Mar 2016

Notice of Results

17^th Mar 2016

EKF Diagnostics Holdings plc announces Notice of Results.

Trading update

3^rd Feb 2016

EKF Diagnostics Holdings plc announces a trading update for the year ended 31 December 2015.

TR-1 notification of major interest in shares

20^th Jan 2016

TR-1 notification of major interest in shares

18^th Jan 2016

TR-1 notification of major interest in shares

15^th Jan 2016

Pages:

Archive

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF Publishes Guide to Good Capillary Blood Sampling

Incorrect capillary blood sampling is most common reason for inaccurate POC hemoglobin results.

Quo Lab takes off in Italy

In a drive to improve management of diabetes, a campaign was launched in Italy to raise awareness introduction of EKF's Quo Lab system in all hospitals of the the Lazio region.

New UltraCrit Training Video

EKF secures FDA clearance for DiaSpect Tm POC hemoglobin analyzer

Easy to use, reagent-free analyzer cleared for use in POC & CLIA waived settings.

Shelf-life extension for DiaSpect HBT Controls

We are pleased to announce that the DiaSpect HBT controls for the DiaSpect Tm have been modified to enhance shelf-life to 11 months from date of production. The new controls will have a more ‘blood-like’ look and feel but remain classified as a non-hazardous product.